Top

Published in:

01-08-2012 | Gynecologic Oncology

Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

Authors: J. B. Engel, A. V. Schally, S. Buchholz, S. Seitz, G. Emons, O. Ortmann

Published in: Archives of Gynecology and Obstetrics | Issue 2/2012

Abstract

Receptors luteinizing hormone-releasing hormone (LHRH) are expressed in about 80 % of human endometrial and ovarian cancers and account for more than 50 % of breast cancers including triple negative breast cancers. Apart from the pituitary and reproductive organs, no other organs or hematopoietic stem cells express LHRH (GnRH) receptors. Thus, these receptors can be regarded as an ideal target for a personalized medicine approach in cancer therapy. AEZS-108 (formerly known as AN-152) in which doxorubin is linked to the LHRH agonist [d-Lys⁶]LHRH, appears to be the most advanced compound in late stage clinical development. Results of phase I and phase II clinical trials in patients with gynecological cancers demonstrated anticancer activity without any cardiotoxicity even in highly pretreated patients. AEZS-108 is therefore being considered for phase II trials in triple negative breast cancers and phase III studies in advanced endometrial cancers positive for LHRH-receptor. EP-100 is a membrane-disrupting peptide targeted to LHRH receptors, which is undergoing early clinical studies in ovarian cancer patients.

Schally AV, Engel JB, Emons G et al (2011) Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 8:11–25PubMedCrossRef

Engel JB, Schally AV (2007) Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3:157–167PubMedCrossRef

Schally AV, Comaru-Schally AM, Nagy A et al (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22:248–291PubMedCrossRef

Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15:300–310PubMedCrossRef

Nagy A, Schally AV, Armatis P et al (1996) Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 93:7269–7273PubMedCrossRef

Halmos G, Nagy A, Lamharzi N, Schally AV (1999) Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 136(2):129–136PubMedCrossRef

Westphalen S, Kotulla G, Kaiser F et al (2000) Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17:1063–1069PubMed

Gunthert AR, Grundker C, Bongertz T et al (2004) Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 191:1164–1172PubMedCrossRef

Schally AV, Nagy A (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 72:2305–2320PubMedCrossRef

10.

Emons G, Sindermann H, Engel J et al (2009) Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 90:15–18PubMedCrossRef

11.

Engel JB, Schally AV, Dietl J et al (2007) Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 4:652–658PubMedCrossRef

12.

Fekete M, Wittliff JL, Schally AV (1989) Characteristics and distribution of receptors for [d-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3:137–147PubMedCrossRef

13.

Bajo AM, Schally AV, Halmos G, Nagy A (2003) Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 9:3742–3748PubMed

14.

Kahan Z, Nagy A, Schally AV et al (2000) Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 59:255–262PubMedCrossRef

15.

Buchholz S, Seitz S, Schally AV et al (2009) Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. Int J Oncol 35:789–796PubMed

16.

Foest C, Duwe F, Hellriegel M et al (2011) Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 25:1481–1487

17.

Emons G, Ortmann O, Becker M et al (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53:5439–5446PubMed

18.

Emons G, Pahwa GS, Brack C et al (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25:215–221PubMedCrossRef

19.

Srkalovic G, Schally AV, Wittliff JL et al (1998) Presence and characteristics of receptors for [d-Trip⁶]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 12:489–498PubMed

20.

Volker P, Grundker C, Schmidt O et al (2002) Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186:171–179PubMedCrossRef

21.

Miyazaki M, Nagy A, Schally AV et al (1997) Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 89:1803–1809PubMedCrossRef

22.

Arencibia JM, Schally AV, Krupa M et al (2001) Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol 19:571–577PubMed

23.

Srkalovic G, Wittliff JL, Schally AV (1990) Detection and partial characterization of receptors for [d-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50:1841–1846PubMed

24.

Emons G, Schröder B, Ortmann O et al (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77:1458–1464PubMedCrossRef

25.

Grundker C, Volker P, Griesinger F et al (2002) Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 187:528–537PubMedCrossRef

26.

Engel JB, Keller G, Schally AV et al (2005) Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril 83(Suppl 1):1125–1133PubMedCrossRef

27.

Buchholz S, Keller G, Schally AV et al (2006) Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. PNAS 103(27):10403–10407PubMedCrossRef

28.

Guenther E, Teifel M, Engel JB et al (2006) Targeting doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152). EJC Suppl 4(12):159

29.

Emons G, Kaufmann M, Gorchev G et al (2010) Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 119:457–461PubMedCrossRef

30.

Emons G, Tomov S, Harter P et al (2010) Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J Clin Oncol (ASCO meeting abstracts 28(15) part 1:Abstract 5035)

31.

Emons G, Sehouli J, Gorchev G et al (2010) Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. EJC Suppl 8(7):120

32.

Leuschner C, Keener J, McCabe R, Patel N, Alila H (2009) Targeted oncolytic peptide for treatment of ovarian cancers. AACR meeting abstracts, Abstract 4666

33.

(2009) Pharmacodynamics (PD) and pharmacokinetics (PK) study of EP-100 in advanced solid tumors. http://clinicaltrials.gov/ct2/show/NCT00949559

34.

(2011) EP-100 plus paclitaxel versus paclitaxel alone in patients with ovarian cancer (ESP2011-002). http://clinicaltrials.gov/ct2/show/NCT01485848

35.

Sundaram S, Durairaj C, Kadam R, Kompella UB (2009) Luteinizing hormone-releasing hormone receptor-targeted deslorelin–docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 8(6):1655–1665PubMedCrossRef

Title: Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)
Authors: J. B. Engel
A. V. Schally
S. Buchholz
S. Seitz
G. Emons
O. Ortmann
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 2/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2335-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Retroperitoneal vascular aberrations increase the risk of vascular injury during lymphadenectomy in gynecologic cancers

Characteristics and therapy of premenopausal patients with early-onset breast cancer in Germany

Prevalence of female genital mutilation among female infants in Kano, Northern Nigeria

Foley catheter versus intra-vaginal misoprostol for induction of labor in post-term gestations

Prenatal screening characteristics in Emanuel syndrome: a case series and review of the literature

Effects of the menstrual cycle phases on the tilt testing results in vasovagal patients